As more and more biopharma innovators seek to realize the immense potential offered by viruses to deliver highly efficient, safe, and efficacious targeted therapies, there’s another need growing right alongside: to have an experienced, capable CDMO partner to guide next-generation viral development and manufacturing.
At Emergent, we’re ready to be that CDMO partner for you. We have foundational expertise in live viral development and manufacturing, among our other core competencies. And we invest heavily in the tools and know-how to deliver on the promise of emerging viral platforms.
Today, for example, that investment has extended into new capabilities at our Rockville, Maryland site. Our current isolator line features integrated BSL2 containment through parts preparation, filling, lyophilization, capping, and exterior vial decontamination. Those capabilities have been augmented through the addition of a second BSL2 line, the INTEGRA, with the same end-to-end functions and:
| Technologies | Scale | Key Equipment |
|---|---|---|
|
*Anticipated to be available Q1 2023 |
|
If you are interested in working with Emergent, want to find out more information about our CDMO services, or would like to have us contact you for any reason, please use this web form to send us your information or questions.
Viral